Publications (204) Publications in which a researcher has participated

filter_list

2025

  1. Disease activity in patients with idiopathic inflammatory myopathy according to time since diagnosis and positivity to antisynthetase autoantibodies: data from the Myo-Spain registry

    Arthritis research & therapy, Vol. 27, Núm. 1, pp. 5

  2. Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors

    Pharmaceuticals, Vol. 18, Núm. 1

2024

  1. An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

    Journal of Clinical Medicine, Vol. 13, Núm. 5

  2. Childhood-Onset Non-Infectious Uveitis in the “Biologic Era”. Results From Spanish Multicenter Multidisciplinary Real-World Clinical Settings

    Ocular Immunology and Inflammation, Vol. 32, Núm. 9, pp. 2159-2169

  3. Cyclosporine A in hospitalized COVID-19 pneumonia patients to prevent the development of interstitial lung disease: a pilot randomized clinical trial

    Scientific Reports, Vol. 14, Núm. 1

  4. Espondiloartritis juvenil. Artritis relacionada con entesitis

    Manual SER de diagnóstico y tratamiento en reumatología pediátrica (Ergon), pp. 105-110

  5. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica, Vol. 162, Núm. 10, pp. 470-476

  6. Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: UVEDAI©

    Ophthalmology and Therapy, Vol. 13, Núm. 6, pp. 1669-1682

  7. Radiographic Progression in Sacroiliac Joints in Patients With Axial Spondyloarthritis: Results From a Five-Year International Observational Study

    ACR Open Rheumatology, Vol. 6, Núm. 2, pp. 103-110

  8. Raynaud's phenomenon and digital ischaemia induced by ixekizumab

    Rheumatology (Oxford, England), Vol. 63, Núm. 1

  9. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. AB1470 Janus Kinase Inhibitors in Severe Inflammatory Ocular Pathology. Multicenter Study and Literature Review

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1963.2-1964

  3. Biological sequential therapy with rituximab-belimumab in patients with recurrent lupus nephritis

    Reumatologia Clinica

  4. Correction to: Validation of UVEDAI: An Index for Evaluating the Level of Inflammatory Activity in Uveitis (Ophthalmology and Therapy, (2023), 12, 2, (1045-1055), 10.1007/s40123-023-00654-8)

    Ophthalmology and Therapy

  5. Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry

    Respiratory research, Vol. 24, Núm. 1, pp. 19

  6. POS0652 Interobserver Reliability and Sensitivity to Change of a Composite Ocular Inflammatory Activity Index: Uvedai

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 604-605

  7. POS0793-HPR Observational Study in Real Clinical Practice of the Treatment of Non-Infectious Uveitis (PÓSTER)

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 689.2-690

  8. Rápida respuesta a rituximab en un paciente con síndrome antisintetasa asociado a anti-Ro52-Jo1 que debuta con enfermedad intersticial rápidamente progresiva y hemorragia alveolar difusa

    Revista de Patologia Respiratoria, Vol. 26, Núm. 3, pp. 76-79

  9. SER recommendations for the treatment of uveitis

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 465-477